The Efficacy and The Safety of Ultrasound-guided Ablation Therapy for Treating Papillary Thyroid Microcarcinoma

Chen, Jifan; Cao, Jing; Qiu, Fuqiang; Huang, Pintong

doi:10.7150/jca.36289

Cited by 23 publications

(31 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Large blood vessels should be avoided in advance. (4) Operators should be proficient in basic techniques of ablation, such as the moving shot technique, the multiple overlapping shot technique, the hydrodissection technique, and leveraged pry-off method (14)(15)(16)(17). Insufficient experience or unskilled operation can easily lead to failure of treatment, and even the risk of uncontrollable bleeding that requires conversion to open surgery.…”

Section: Discussionmentioning

confidence: 99%

Intracystic Hemorrhage and Its Management During Ultrasound-Guided Percutaneous Microwave Ablation for Cystic Thyroid Nodules

Dong

Sun

et al. 2020

Front. Endocrinol.

View full text Add to dashboard Cite

Background: Intracystic hemorrhage can present occasionally during ultrasound-guided percutaneous microwave ablation (PMWA) for cystic thyroid nodules. It can affect treatment outcome, can lead to ablation failure, and even conversion to open surgery. We aim to avoid such cases in the future by exploring their causes and management. Methods: From March 2017 to December 2019, we retrospectively studied 87 cystic thyroid nodules in 59 patients who underwent PMWA in the First Hospital of Jilin University. All patients were followed at 1, 3, 6, and 12 months after treatment. Results: All patients completed the treatment successfully. Nine cystic thyroid nodules presented with intracystic hemorrhage during the ultrasound-guided PMWA, giving an incidence of 10.3% (9/87 cysts). Larger cystic thyroid nodules were more likely to develop intracystic bleeding during ultrasound-guided PMWA. Intracystic hemorrhage resulted in significantly prolonged ablation time and had a negative effect on treatment outcome. No patients had other complications, but temporary post-operative pain and local swelling were more obvious in patients with intracystic hemorrhage. Conclusion: Intracystic hemorrhage is not rare during ultrasound-guided PMWA for cystic thyroid nodules. Doctors should pay more attention to it, learn to manage it and try to avoid it in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Intracystic Hemorrhage and Its Management During Ultrasound-Guided Percutaneous Microwave Ablation for Cystic Thyroid Nodules

Dong

Sun

et al. 2020

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…By retrieving pertinent literatures, we found that there has been one case report of a patient with thyroid cancer presenting with TIO and bone metastasis. 17,18 Although this patient had a history of papillary thyroid carcinoma, testing indicated that the patient's TIO and bone metastases were due to a phosphaturic mesenchymal tumour. 19 Genetic mechanism by which tumours express FGF-23 is not well known.…”

Section: Discussionmentioning

confidence: 97%

Left maxillary sinus tumour‐induced hypophosphataemic osteomalacia and combined with thyroid papillary carcinoma: a case report and literature review

Dong

Liu

et al. 2020

Internal Medicine Journal

View full text Add to dashboard Cite

Tumour-induced osteomalacia (TIO) is a rare disease characterised by hypophosphataemia and clinical symptoms of osteomalacia. Herein we report the case of a 29-year-old man who was admitted to hospital with progressive bone pain and was diagnosed with TIO caused by maxillary sinus tumours. In the preoperative evaluation, it was found that the patient had thyroid malignant tumours at the same time. Two operations were performed separately on the left maxillary sinus tumour and thyroid tumour after complete examination. After tumour resections, the symptoms of bone pain were relieved and the level of blood phosphorus was restored, long-term replacement therapy was needed for thyroid. When a patient is diagnosed with TIO, it is necessary to screen for the presence of other malignant tumours and explore the treatment options in order to benefit patients preferably. AbstractMechanical ventilation as a resource is limited and may lead to poor outcomes in at-risk populations. Critical care supports may not be preferred by those at risk of deterioration in the COVID-19 setting. Patient-centred communication and shared decision-making should continue to remain central to clinical practice.

show abstract

“…Papillary thyroid microcarcinoma (PTMC) with a tumor diameter ≤1 cm occurs in >50% of all new-onset thyroid cancer types, and its incidence has been increasing rapidly over the last several decades worldwide ( 9 , 10 ). Clinically, numerous studies have reported that PTMC had a favorable prognosis in the majority of cases following surgical interventions ( 11 – 13 ). However, PTMC tumor growth is usually slow and certain patients developed clinically problematic tumor growth after multiple years of observation ( 14 , 15 ).…”

Section: Introductionmentioning

confidence: 99%

Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma

et al. 2021

View full text Add to dashboard Cite

With the increasing incidence of papillary thyroid cancer (PTC), it is important to risk-stratify patients who may have a more aggressive tumor biology. The present study aimed to evaluate the risk factors for lymph node metastasis (LNM) in patients with PTC, which may provide a significant reference for clinical diagnosis and treatment. In total, 1,045 patients with PTC [313 with PT microcarcinoma (PTMC) and 732 with non-PTMC] between August 2016 and August 2019 were investigated. The B-type Raf kinase (BRAF) V600E mutation was tested in all samples. The clinical data (sex, age, tumor location, sample type and pathological features) were retrospectively analyzed. Logistic regression analysis was performed to evaluate independent risk factors for LNM. A total of 181/313 (57.8%) PTMC cases and 145/732 (19.8%) non-PTMC cases had a BRAF V600E mutation. In the PTMC cases, significant differences in sex and sample type were identified (BRAF V600E mutation vs. wild-type). In the non-PTMC cases, significant differences in sex and age were identified (BRAF V600E mutation vs. wild-type). Female sex and tumor diameter ≤1 cm were significant independent predictors of LNM in PTC. In PTMC, female sex was a significant independent predictor of LNM. A bilateral tumor was an independent protective factor for LNM in PTC, PTMC and non-PTMC. The BRAF V600E mutation rate of ultrasound-guided fine-needle aspiration cytology was higher compared with FFPE in PTMC (P=0.018). In contrast to previous studies, the results of the present study suggested that being female and having a tumor of diameter ≤1 cm were risk factors for LNM, and that the BRAF wild-type of PTMC may be more aggressive than other types. Notably, the position of the tumor in the bilateral thyroid was also an independent protective factor for LNM. Therefore, ultrasound-guided fine-needle aspiration should be recommended for gene analysis (BRAF V600E) in PTMC. In addition, clinicians should consider an individualized treatment according to gene mutations, sex, age, tumor size and the location of the tumor, in order to achieve an improved therapeutic efficacy.

show abstract

The Efficacy and The Safety of Ultrasound-guided Ablation Therapy for Treating Papillary Thyroid Microcarcinoma

Cited by 23 publications

References 68 publications

Intracystic Hemorrhage and Its Management During Ultrasound-Guided Percutaneous Microwave Ablation for Cystic Thyroid Nodules

Intracystic Hemorrhage and Its Management During Ultrasound-Guided Percutaneous Microwave Ablation for Cystic Thyroid Nodules

Left maxillary sinus tumour‐induced hypophosphataemic osteomalacia and combined with thyroid papillary carcinoma: a case report and literature review

Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma

Contact Info

Product

Resources

About